SCHEMBL2117312

SCHEMBL2117312

Cc1ccc(OCCCn2ccc3ccc(C(=O)NO)cc3c2=O)cc1

nearest known ligand 0.50

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 5/20 0.45
HDAC3 O15379 4/20 0.45
HDAC1 Q13547 4/20 0.45
HDAC8 Q9BY41 3/20 0.45
HDAC11 Q96DB2 2/20 0.45
HDAC2 Q92769 2/20 0.45
HDAC4 P56524 1/20 0.45
HDAC7 Q8WUI4 1/20 0.45
HDAC10 Q969S8 1/20 0.45
HDAC9 Q9UKV0 1/20 0.45
HDAC5 Q9UQL6 1/20 0.45
NCOR2 Q9Y618 1/20 0.45
MCL1 Q07820 4/20 0.44
NPC1 O15118 1/20 0.42
TNF P01375 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2619364 0.95 HDAC6 (0.46) HDAC6HDAC3HDAC1HDAC8HDAC11
SCHEMBL2116350 0.92 HDAC6 (0.55) HDAC6HDAC3HDAC1HDAC8HDAC11
SCHEMBL2611306 0.89 HDAC6 (0.52) HDAC6HDAC3HDAC1HDAC8HDAC11
SCHEMBL4550099 0.88 MCL1 (0.54) HDAC6HDAC3HDAC1HDAC8HDAC11
SCHEMBL2619282 0.87 HDAC6 (0.50) HDAC6HDAC3HDAC1HDAC8HDAC11
SCHEMBL10284845 0.87 TNF (0.43) HDAC6HDAC3HDAC1HDAC8HDAC11
SCHEMBL2116432 0.86 HDAC6 (0.56) HDAC6HDAC3HDAC1HDAC8HDAC11
SCHEMBL2117041 0.86 HDAC6 (0.44) HDAC6HDAC3HDAC1HDAC8HDAC11
SCHEMBL10267901 0.86 SMPD1 (0.49) HDAC6HDAC3HDAC1HDAC8HDAC11
SCHEMBL4550036 0.84 HDAC6 (0.41) HDAC6HDAC3HDAC1HDAC8HDAC11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160039789-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. 2016-02-11 US disclosed
US-20160039789-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. 2016-02-11 US disclosed
US-8765773-B2 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-07-01 US disclosed
US-8765773-B2 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-07-01 US disclosed
WO-2012054332-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-04-26 WO disclosed
US-20120094997-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-04-19 US disclosed
US-20120094997-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120094997-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC1, HDAC5 HDAC6 1/4885HDAC3 5/4885HDAC1 2/4885
US-20160039789-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC1, HDAC5 HDAC6 1/4885HDAC3 5/4885HDAC1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.